Athira Pharma, Inc. (NASDAQ:LONA) Stock Has Consensus Target Price of $17.33

Athira Pharma, Inc. (NASDAQ:LONA) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $17.33.

LONA has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a report on Friday, August 7th. Mizuho reduced their price objective on shares of Athira Pharma from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Wednesday, August 19th. Finally, Citizens Jmp lowered their target price on shares of Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating for the company in a report on Monday, August 17th.

Hedge Funds Weigh In On Athira Pharma

Institutional investors have recently modified their holdings of the business. Seven Fleet Capital Management LP acquired a new position in Athira Pharma during the fourth quarter worth about $969,000. Commodore Capital LP acquired a new stake in shares of Athira Pharma in the 4th quarter worth approximately $3,515,000. Finally, Spruce Street Capital LP purchased a new position in Athira Pharma in the 4th quarter valued at approximately $2,980,000. 57.12% of the stock is owned by institutional investors and hedge funds.

Athira Pharma Trading Up 22.7%

Shares of NASDAQ:LONA opened at $4.38 on Tuesday. Athira Pharma has a 52 week low of $2.21 and a 52 week high of $14.21. The company’s 50 day moving average is $6.99 and its two-hundred day moving average is $8.42. The company has a market cap of $41.13 million, a PE ratio of -1.04 and a beta of 2.12.

Athira Pharma (NASDAQ:LONA) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.20). As a group, equities research analysts expect that Athira Pharma will post -2.67 EPS for the current year.

Athira Pharma Company Profile

Athira Pharma, Inc is a biotechnology company focused on developing regenerative medicines for diseases involving neurodegeneration and neurological decline. The company’s research is based on the hepatocyte growth factor (HGF) pathway, which it believes may support neuronal health, repair, and regeneration.

Athira’s lead investigational product is fosgonimeton (also known as ATH-1017), a small-molecule therapy designed to activate the HGF/MET system. The treatment has been studied for Alzheimer’s disease and other neurological conditions, although it remains investigational and has not been approved for commercial use.

Athira was founded in 2011 and is based in the United States.